Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Retrospective Chart Review Study to Evaluate the Demographics and Treatment Patterns of Myelofibrosis in Routine Practice After Ruxolitinib Approval in Turkey

NCT07357441 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT07357441
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07357441 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Retrospective Chart Review Study to Evaluate the Demographics and Treatment Patterns of Myelofibrosis in Routine Practice After Ruxolitinib Approval in Turkey
Lead sponsor
Novartis Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
April 7, 2022
Completion date
June 28, 2023
Enrollment
355 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis